Britannia Life Sciences Inc.
BLAB
CNSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -22.31% | 95.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -22.31% | 95.95% | |||
| Cost of Revenue | -37.76% | 339.34% | |||
| Gross Profit | 1,812.50% | -103.10% | |||
| SG&A Expenses | 254,800.00% | -99.97% | |||
| Depreciation & Amortization | -1.77% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 210.95% | -67.40% | |||
| Operating Income | -1,968.03% | 95.52% | |||
| Income Before Tax | -45.98% | -82.60% | |||
| Income Tax Expenses | -- | -169.85% | |||
| Earnings from Continuing Operations | -64.85% | -69.12% | |||
| Earnings from Discontinued Operations | -- | -77.69% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -67.63% | -70.03% | |||
| EBIT | -1,968.03% | 95.52% | |||
| EBITDA | -26,700.00% | 99.66% | |||
| EPS Basic | -67.70% | -69.96% | |||
| Normalized Basic EPS | -66.67% | 400.00% | |||
| EPS Diluted | -67.70% | -69.96% | |||
| Normalized Diluted EPS | -66.67% | 400.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||